50,000 Shares in Ultragenyx Pharmaceutical Inc. $RARE Acquired by Ishara Investments LP

Posted by Stanley Muller on Jun 18th, 2026

Ishara Investments LP purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 50,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,150,000. Ultragenyx Pharmaceutical comprises approximately 1.3% of Ishara Investments LP’s portfolio, making the stock its 26th largest position.

Other large investors have also bought and sold shares of the company. Assetmark Inc. grew its position in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the last quarter. Huntington National Bank grew its position in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares during the last quarter. Danske Bank A S bought a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $39,000. Smartleaf Asset Management LLC grew its position in Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,169 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth approximately $56,000. 97.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Howard Horn sold 4,683 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $24.90, for a total transaction of $116,606.70. Following the sale, the chief financial officer owned 110,342 shares of the company’s stock, valued at approximately $2,747,515.80. This trade represents a 4.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Shehnaaz Suliman sold 5,740 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the sale, the director directly owned 27,951 shares in the company, valued at $702,129.12. The trade was a 17.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 24,002 shares of company stock valued at $575,039 over the last 90 days. Company insiders own 5.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on RARE shares. Truist Financial upgraded Ultragenyx Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, March 25th. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. Barclays decreased their price objective on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. JPMorgan Chase & Co. decreased their price objective on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a research report on Thursday, March 12th. Finally, Cantor Fitzgerald increased their price objective on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a research report on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $59.56.

Get Our Latest Research Report on RARE

Ultragenyx Pharmaceutical Stock Up 8.3%

NASDAQ:RARE opened at $26.91 on Thursday. Ultragenyx Pharmaceutical Inc. has a 12-month low of $18.29 and a 12-month high of $42.37. The firm has a market capitalization of $2.65 billion, a P/E ratio of -4.40 and a beta of 0.37. The stock’s fifty day simple moving average is $24.17 and its 200-day simple moving average is $24.91.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The company had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. During the same quarter in the prior year, the business earned ($1.57) earnings per share. The firm’s revenue for the quarter was down 2.2% on a year-over-year basis. As a group, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.53 earnings per share for the current year.

About Ultragenyx Pharmaceutical

(Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.